Cargando…

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost‐effectiveness

INTRODUCTION: A vaginal ring containing dapivirine is effective for HIV prevention as pre‐exposure prophylaxis (PrEP). We evaluated the potential epidemiological impact and cost‐effectiveness of dapivirine vaginal ring PrEP among 22‐ to 45‐year‐old women in KwaZulu‐Natal, South Africa. METHODS: Usin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glaubius, Robert, Ding, Yajun, Penrose, Kerri J, Hood, Greg, Engquist, Erik, Mellors, John W, Parikh, Urvi M, Abbas, Ume L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510112/ https://www.ncbi.nlm.nih.gov/pubmed/31074936 http://dx.doi.org/10.1002/jia2.25282

Ejemplares similares

Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention
por: Glaubius, Robert L., et al.
Publicado: (2016)

Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention
por: Reidy, Meghan, et al.
Publicado: (2019)

HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial
por: Parikh, Urvi M., et al.
Publicado: (2021)

Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women
por: Shapley-Quinn, Mary Kate, et al.
Publicado: (2022)

Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study
por: Abbas, Ume L., et al.
Publicado: (2019)

Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention
por: Palanee-Phillips, Thesla, et al.
Publicado: (2015)

Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
por: Mayo, Ashley J., et al.
Publicado: (2021)

Increased Dapivirine Tissue Accumulation through Vaginal Film Codelivery of Dapivirine and Tenofovir
por: Akil, Ayman, et al.
Publicado: (2014)

Drug Resistance After Failure of WHO Recommended First-Line Antiretroviral Regimen for Adult HIV-1 Infection in South Africa: A Modeling Analysis
por: Ding, Yajun, et al.
Publicado: (2017)

Physiologically‐based pharmacokinetic model of vaginally administered dapivirine ring and film formulations
por: Kay, Katherine, et al.
Publicado: (2018)

Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda
por: Kusemererwa, Sylvia, et al.
Publicado: (2022)

Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV‐1 acquisition: a secondary analysis from a randomized, placebo‐controlled trial
por: Brown, Elizabeth R, et al.
Publicado: (2020)

Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls
por: Farr Zuend, Christina, et al.
Publicado: (2021)

Dapivirine Bioadhesive Vaginal Tablets Based on Natural Polymers for the Prevention of Sexual Transmission of HIV
por: Cazorla-Luna, Raúl, et al.
Publicado: (2019)

Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States
por: Liu, Albert Y, et al.
Publicado: (2021)

Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel
por: Dallal Bashi, Yahya H., et al.
Publicado: (2021)

Refining the in vitro release test method for a dapivirine-releasing vaginal ring to match in vivo performance
por: Murphy, Diarmaid J., et al.
Publicado: (2021)

Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial
por: Palanee-Phillips, Thesla, et al.
Publicado: (2018)

Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
por: Bhavaraju, Neeraja, et al.
Publicado: (2021)

Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa
por: Nel, Annalene, et al.
Publicado: (2016)

In vitro drug release, mechanical performance and stability testing of a custom silicone elastomer vaginal ring releasing dapivirine and levonorgestrel
por: Murphy, Diarmaid J., et al.
Publicado: (2022)

Rational Design of a Multipurpose Bioadhesive Vaginal Film for Co-Delivery of Dapivirine and Levonorgestrel
por: Li, Jing, et al.
Publicado: (2019)

Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP)
por: Abbas, Ume L., et al.
Publicado: (2011)

Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial
por: Dezzutti, Charlene S., et al.
Publicado: (2016)

Adolescent Girls and Young Women’s Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis
por: Young, Alinda M., et al.
Publicado: (2023)

Design of Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticles for Vaginal Co-Delivery of Griffithsin and Dapivirine and Their Synergistic Effect for HIV Prophylaxis
por: Yang, Haitao, et al.
Publicado: (2019)

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa
por: Penrose, Kerri J, et al.
Publicado: (2018)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania
por: Tubert, Julia, et al.
Publicado: (2021)

Inhibition of HIV Virus by Neutralizing Vhh Attached to Dual Functional Liposomes Encapsulating Dapivirine
por: Wang, Scarlet Xiaoyan, et al.
Publicado: (2016)

Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings
por: Abbas, Ume L., et al.
Publicado: (2007)

Multiple dosage forms of the NNRTI microbicide dapivirine: product development and evaluation
por: Romano, Joseph
Publicado: (2006)

Antitumor Activity and Mechanism of a Reverse Transcriptase Inhibitor, Dapivirine, in Glioblastoma
por: Liu, Weiwen, et al.
Publicado: (2018)

Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions
por: Zheng, Ruohui, et al.
Publicado: (2022)

Vaginal rings for delivery of HIV microbicides
por: Malcolm, R Karl, et al.
Publicado: (2012)

Investigating the Contribution of Drug-Metabolizing Enzymes in Drug-Drug Interactions of Dapivirine and Miconazole
por: Valicherla, Guru Raghavendra, et al.
Publicado: (2021)

Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study
por: Garcia, Morgan, et al.
Publicado: (2021)

Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring
por: Stoner, Marie C. D., et al.
Publicado: (2022)

Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)
por: Ngure, Kenneth, et al.
Publicado: (2023)

Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009)
por: Parikh, Urvi M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_43hkrl75gojhrciqgii83im1vg